The Novel Deacetylase Inhibitor AR-42 Demonstrates Pre-Clinical Activity in B-Cell Malignancies In Vitro and In Vivo

BACKGROUND: While deacetylase (DAC) inhibitors show promise for the treatment of B-cell malignancies, those introduced to date are weak inhibitors of class I and II DACs or potent inhibitors of class I DAC only, and have shown suboptimal activity or unacceptable toxicities. We therefore investigated...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Autori principali: Lucas, David M., Alinari, Lapo, West, Derek A., Davis, Melanie E., Edwards, Ryan B., Johnson, Amy J., Blum, Kristie A., Hofmeister, Craig C., Freitas, Michael A., Parthun, Mark R., Wang, Dasheng, Lehman, Amy, Zhang, Xiaoli, Jarjoura, David, Kulp, Samuel K., Croce, Carlo M., Grever, Michael R., Chen, Ching-Shih, Baiocchi, Robert A., Byrd, John C.
Natura: Artigo
Lingua:Inglês
Pubblicazione: Public Library of Science 2010
Soggetti:
Research Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC2880605/
https://ncbi.nlm.nih.gov/pubmed/20532179
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1371/journal.pone.0010941
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi